<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical use of dofetilide</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical use of dofetilide</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical use of dofetilide</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rod Passman, MD, MSCE</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elsa-Grace Giardina, MD, MS, FACC, FACP, FAHA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark S Link, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">Dofetilide</a> is a class III antiarrhythmic agent  (<a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">table 1</a>) available for the acute termination of atrial fibrillation or flutter, as well as prevention of atrial fibrillation or flutter recurrence. Dofetilide has also been used in an off-label manner to treat paroxysmal supraventricular tachycardias. Some investigators have studied the efficacy of dofetilide in the treatment of life-threatening ventricular arrhythmias, although the drug is not approved for this indication. In contrast to some other antiarrhythmic medications, dofetilide appears to be hemodynamically safe for use in patients with heart failure or a prior myocardial infarction [<a href="#rid1">1</a>]. Because of a relatively high risk of torsades de pointes as an adverse effect of dofetilide, it has extensive contraindications for its use and rigorous dosing guidelines. </p><p>The basic pharmacologic properties of <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>, its clinical uses, and its safety profile are discussed in detail here. Alternative treatment approaches for supraventricular and ventricular arrhythmias are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials"</a> and  <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations"</a> and  <a class="medical medical_review" href="/z/d/html/902.html" rel="external">"Atrioventricular nodal reentrant tachycardia", section on 'Initial management'</a> and  <a class="medical medical_review" href="/z/d/html/1040.html" rel="external">"Sustained monomorphic ventricular tachycardia in patients with structural heart disease: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ELECTROPHYSIOLOGY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">Dofetilide</a> is a class III antiarrhythmic agent that blocks the delayed rectifier cardiac potassium channel and prolongs repolarization  (<a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">table 1</a>). Dofetilide has relative selectivity for blocking the rapidly-activating component of the delayed rectifier potassium current (IKr) at concentrations of 10 to 30 nanomol/L [<a href="#rid2">2,3</a>]. At these concentrations, it does not block the slow component of the delayed rectifier potassium current (IKs) or the inward rectifier (IKi) and does not affect calcium currents. Evidence from one study shows that dofetilide and several other drugs known to cause torsades de pointes (d-sotalol, <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">thioridazine</a>, and <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>) increase the late sodium current (I<sub>NaL</sub>) in cardiac cells, an action (IC<sub>50 </sub>= 0.1 micromol/L) that could contribute to their arrhythmogenic potential [<a href="#rid4">4</a>].</p><p>As a result of its electrophysiologic actions on I<sub>Kr </sub>and possibly I<sub>NaL</sub>, <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> has a selective effect on the QT interval of the surface ECG. In clinical electrophysiologic studies, it prolongs the QT interval with little, if any, effect on QT dispersion [<a href="#rid5">5</a>]. Purkinje fibers from female dogs are more sensitive to dofetilide than fibers from male dogs, which is consistent with the threefold greater incidence of torsades de pointes in women and the observation that women are more likely to require dose reduction or discontinuation than men [<a href="#rid6">6,7</a>].</p><p>Like other class III agents, <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> exhibits reverse use dependency (greater prolongation of repolarization and the refractory period during slower heart rates). The drug prolongs the effective refractory period of atrial and ventricular myocardium and accessory pathways, but it has no effect on conduction parameters, sinus cycle length, or sinus node recovery [<a href="#rid8">8,9</a>]. (See  <a class="medical medical_review" href="/z/d/html/895.html" rel="external">"Cardiac excitability, mechanisms of arrhythmia, and action of antiarrhythmic drugs"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PHARMACOLOGIC DATA/PHARMACOKINETICS</span><span class="headingEndMark"> — </span>The oral doses of <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> that have been used in clinical trials range from 125 to 500 mcg twice daily. Peak plasma concentrations are seen two to three hours after oral dosing when fasting. Dofetilide is completely absorbed after oral administration, and bioavailability ranges from 75 to 100 percent [<a href="#rid10">10</a>]. Elimination is predominantly renal (80 percent), with only 20 percent hepatic conversion to inactive metabolites [<a href="#rid11">11</a>]. The elimination half-life is approximately ten hours after intravenous or oral administration. Clearance has been estimated to be 0.35 L/hour/kg [<a href="#rid12">12</a>].</p><p>There is a very linear relationship between the dose administered, plasma concentration of <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>, and its effect on the QT interval after both oral and intravenous administration [<a href="#rid12">12</a>]. This observation indicates that it is unlikely that there are important effects of the metabolites on potassium channels and supports earlier work examining the activities of the metabolites in vitro. </p><p>Although some safety and efficacy trials with intravenous <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> have been performed, dofetilide is not available for intravenous administration in the United States [<a href="#rid13">13-17</a>]. </p><p class="headingAnchor" id="H3247669703"><span class="h1">METABOLISM AND DRUG INTERACTIONS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">Dofetilide</a>, like most other potassium channel blockers, is metabolized predominantly by the CYP3A4 family of enzymes in the liver and gastrointestinal tract. This means that it is likely to interact with drugs that inhibit CYP3A4, such as <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>, <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>, or <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a>, resulting in higher and potentially toxic levels of dofetilide [<a href="#rid18">18</a>]. The QT-prolonging effects and the risk of torsades de pointes can be increased by coadministration of dofetilide with other drugs that also prolong the QT interval or drugs that interfere with renal elimination of dofetilide (eg, <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">cimetidine</a>, <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>, <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a>, alone or in combination with sulfamethoxazole, <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">prochlorperazine</a>, <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">hydrochlorothiazide</a>, alone or in combination with <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">triamterene</a>, megestrol, <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a>, or ketoconazole). Additional information can also be found using the <a class="external" href="/drug-interactions">drug interactions program</a>. Dofetilide has been studied in experiments that examine concomitant administration of QT-prolonging drugs. Some examples have shown nearly additive effects on QT interval and action potential duration, while others have shown inhibitory effects dependent on the order in which the drugs were administered [<a href="#rid19">19-21</a>]. As a result, while caution is appropriate to avoid additive or synergistic effects, resulting in QT prolongation and increased risk of torsades de pointes, the presence of inhibitory effects of certain drug-drug combinations indicates the need for additional research to gain a better understanding of drug-drug interaction on the QT interval and action potential duration. There is frequent use of diuretics among those requiring dofetilide. The concomitant use of hydrochlorothiazide almost doubles the degree of heart-rate–corrected QT interval prolongation related to decreased dofetilide clearance and diuretic-induced hypokalemia [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H6"><span class="h1">DRUG APPROVAL AND RESTRICTIONS</span><span class="headingEndMark"> — </span>The US Food and Drug Administration (FDA) approved the use of <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> for the cardioversion of atrial fibrillation (AF) and atrial flutter (AFl) to normal sinus rhythm and for maintenance of normal sinus rhythm in symptomatic patients with AF/AFl. Several other countries worldwide have also approved its use; however, widespread approval and usage have been somewhat limited due to safety concerns. Because of the risk of torsades de pointes, the FDA recommends that patients initiating or reinitiating dofetilide must be placed in a facility for a minimum of three days that can provide dosing based on estimated creatinine clearance, cardiac monitoring, and cardiac resuscitation. The majority (ie, 75 percent) of episodes of torsades de pointes have occurred within the three-day period of initial dosing and at the time of peak increase in the QT interval [<a href="#rid23">23</a>]. However, late occurrence is possible and has been reported.</p><p class="headingAnchor" id="H7"><span class="h1">PROTOCOL FOR ADMINISTRATION</span><span class="headingEndMark"> — </span>In an effort to optimize efficacy and safety, the initiation or reinitiation of <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> should occur in a controlled fashion according to the FDA-recommended dose protocol  (<a class="graphic graphic_figure graphicRef64845" href="/z/d/graphic/64845.html" rel="external">figure 1</a>). </p><p>Deviation from the FDA-recommended protocol is required in up to 45 percent of cases, often due to adverse events [<a href="#rid24">24</a>]. When patients require reinitiation of therapy or dose increase, experience suggests that the recommended protocol and hospital admission should be implemented [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H759955701"><span class="h1">SPECIFIC INDICATIONS</span><span class="headingEndMark"> — </span>Because <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> can cause life-threatening ventricular arrhythmias, it is recommended that it should be reserved for patients in whom atrial fibrillation/atrial flutter (AF/AFl) is highly symptomatic or has resulted in heart failure. Although not approved for use, it has been evaluated in small studies in patients with other supraventricular arrhythmias and ventricular tachycardia. </p><p class="headingAnchor" id="H10"><span class="h2">Oral dofetilide for atrial fibrillation/atrial flutter termination and prevention</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">Dofetilide</a> is indicated for the conversion of atrial fibrillation/atrial flutter (AF/AFl) and maintenance of normal sinus rhythm (delay in time to recurrence of AF/AFl) in patients whose arrhythmia is of greater than one-week duration and who have been converted to normal sinus rhythm. </p><p>Oral <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> has been evaluated for the cardioversion of atrial fibrillation (AF) or atrial flutter (AFl) to normal sinus rhythm and for the prevention of recurrent AF or atrial flutter.</p><p class="bulletIndent1"><span class="glyph">●</span>To evaluate the efficacy of <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> in termination of atrial arrhythmias, the SAFIRE-D study randomly assigned 325 patients with AF (n = 277) or AFl (n = 48) to 125, 250, and 500 mcg of dofetilide twice daily or placebo [<a href="#rid26">26</a>]. Overall conversion rates were 6, 10, and 30 percent, respectively, versus 1.2 percent for placebo. At a dose of 500 mcg twice daily, the conversion rates for AF and atrial flutter were 22 and 67 percent, respectively. For those patients who responded to dofetilide, conversion to sinus rhythm occurred within 24 hours in 70 percent and within 36 hours in 91 percent. (See  <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The SAFIRE-D trial also evaluated the long-term efficacy of <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> for maintenance of sinus rhythm in 204 patients with AF who were successfully cardioverted electrically or pharmacologically with dofetilide and maintained on a dofetilide dose of 125, 250, or 500 mcg twice daily or placebo [<a href="#rid26">26</a>]. The probability of remaining in sinus rhythm at one year was 40, 37, and 58 percent versus 25 percent for placebo. The all-cause mortality was the same in the four groups. (See  <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute conversion versus long-term arrhythmia free survival – In retrospective studies of patients who initiated <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> during persistent AF/AFl, between 45 and 56 percent have converted to sinus rhythm during dofetilide loading [<a href="#rid27">27,28</a>]. Female gender, history of AFl, greater number of prior catheter ablations, shorter duration of current AF/AFl, and presentation in AFl were all associated with acute pharmacologic conversion (p = 0.001, 0.05, 0.001, 0.003, and 0.003, respectively) [<a href="#rid27">27</a>]. Pharmacologic conversion was not significantly associated with time to AF/AFl recurrence (HR = 0.79, 95% CI 0.57-1.10, p = 0.2). Acute pharmacologic conversion of persistent AF/AFl to sinus rhythm frequently occurs during dofetilide loading but does not predict long-term arrhythmia control, which was moderate at best.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Comparative efficacy – In an observational study of 5952 consecutive patients with AF who were prescribed <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> (n = 2266), <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a> (n = 488), <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> (n = 539), <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> (n = 1718), or class 1C agents (n = 941) and followed for a median of 18 months, amiodarone, class 1C agents, and sotalol were associated with less AF recurrence than dofetilide or dronedarone [<a href="#rid29">29</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another observational study suggests that when properly initiated and monitored, <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>'s efficacy and safety are comparable to that of <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>. The study assessed rhythm control with dofetilide in 657 patients with AF and/or atrial flutter and AF. Dofetilide was successfully initiated in 87 percent of patients, including 89 percent with persistent AF and 11 percent with paroxysmal AF. During a mean follow-up of 19±7 months, sinus rhythm was maintained in 63 percent of 573 dofetilide-treated patients. At 12 months, dofetilide patients had a similar likelihood of experiencing recurrent atrial arrhythmias compared with 2476 patients on amiodarone for rhythm control (37 versus 39 percent). The efficacy of dofetilide and amiodarone was similar in subgroups, including patients &gt;75 years of age, low ventricular ejection fraction, obesity, renal insufficiency, and prior catheter ablation for AF [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid conversion of patients who were refractory or intolerant of <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> to <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> therapy was successful in 66 percent of 179 patients who had an ICD in place and for whom amiodarone had been discontinued for seven days [<a href="#rid31">31</a>].</p><p></p><p class="headingAnchor" id="H1072509641"><span class="h2">Dofetilide for preventing recurrence of paroxysmal supraventricular tachycardia</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">Dofetilide</a> (500 mcg twice daily) was compared with <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a> (150 mg three times daily) and placebo for the prevention of recurrent paroxysmal supraventricular tachycardia (PSVT) in a trial of 122 patients [<a href="#rid32">32</a>]. After six months of therapy, freedom from episodes of PSVT was the same with dofetilide and propafenone (50 and 54 versus 6 percent for placebo); the median number of episodes of PSVT in those with recurrences was also the same with these two agents (1 and 0.5 versus 5 for placebo).</p><p class="headingAnchor" id="H13"><span class="h2">Ventricular tachyarrhythmias</span><span class="headingEndMark"> — </span>Animal studies have suggested that <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> reduces the incidence of sustained ventricular tachyarrhythmias during acute myocardial ischemia [<a href="#rid33">33</a>]. However, comprehensive studies of dofetilide in patients with life-threatening ventricular tachyarrhythmias are limited.</p><p>Oral <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> (500 mcg twice daily) was compared with oral <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> (160 mg twice daily) in a randomized, crossover comparative trial of 135 patients with ischemic heart disease and ventricular tachycardia (VT) induced during electrophysiologic testing [<a href="#rid34">34</a>]. Patients underwent repeat electrophysiologic testing after three to five days of therapy and then crossed over to the alternate drug. The response rate was the same with dofetilide and sotalol (36 versus 34 percent), but only 18 percent responded to both drugs. Drug-related adverse effects were significantly less frequent with dofetilide.</p><p>Oral <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> has also been evaluated patients with an ICD, yielding mixed results. Among one cohort of 174 patients with an implantable cardioverter-defibrillator (ICD), dofetilide did not reduce the incidence of ICD interventions for ventricular tachycardia or ventricular fibrillation (VF) compared with placebo; however, the incidence of pause-dependent torsades de pointes was significantly higher with dofetilide (17 versus 6 percent for placebo) [<a href="#rid35">35</a>]. However, in a smaller cohort of 30 patients with ICDs for secondary prevention who were treated with dofetilide and followed for an average of 32 months, dofetilide led to significant reductions in VT and VF as well as ICD therapies delivered [<a href="#rid36">36</a>]. </p><p>Pending the completion of additional prospective studies of <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>, we do not suggest its routine use as a first-line antiarrhythmic drug for the treatment of ventricular tachyarrhythmias.</p><p class="headingAnchor" id="H16"><span class="h2">Heart failure</span><span class="headingEndMark"> — </span>Both animal and human studies have shown that <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> does not have a negative inotropic effect on left ventricular contractility [<a href="#rid37">37,38</a>]. In a clinical study of patients with class II or III heart failure, intravenous dofetilide (8 mcg/kg), which is not available in all countries, did not alter left ventricular contractility or ventricular volumes [<a href="#rid38">38</a>]. In addition, because of the limited number of antiarrhythmic medications available for use in patients with heart failure or reduced left ventricular systolic function, there is interest in developing additional antiarrhythmic medications for use in this population. Despite this potential interest, there remain limited data with mixed outcomes regarding the safety and efficacy of dofetilide use in such patients, particularly in those with advanced heart failure.</p><p>There are limited post-approval data and safety outcomes with <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> use in patients with reduced left ventricular ejection fraction. In a retrospective review from a single center, dofetilide as an initial antiarrhythmic strategy for atrial fibrillation in left ventricular ejection fraction ≤35 percent was associated with improvement in left ventricular ejection fraction &gt;35 percent in 73 percent of patients, precluding the need for primary prevention implantable cardioverter defibrillator in most patients [<a href="#rid39">39</a>]. </p><p>The DIAMOND-CHF trial evaluated the safety of <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> compared with placebo in 1518 patients with symptomatic heart failure and left ventricular dysfunction (left ventricular ejection fraction ≤35 percent), including 391 with AF at baseline [<a href="#rid23">23</a>]. After one month of therapy, 12 percent of patients with AF at baseline had sinus rhythm restored compared with only 1 percent receiving placebo. After a mean follow-up of 18 months, there was no overall difference in mortality between the two groups (41 versus 42 percent). In a subsequent analysis, a difference in mortality was noted according to baseline corrected QT (QTc) interval [<a href="#rid40">40</a>]. In those with a QTc interval &lt;429 milliseconds, dofetilide was associated with a significant reduction in mortality (risk ratio 0.4, 95% CI 0.3 to 0.8), while it tended to increase mortality in those with a QTc interval &gt;479 milliseconds (risk ratio 1.3, 95% CI 0.8 to 1.9). In these same patients, the incidence of torsades de pointes was 3.3 percent; three-quarters of these episodes occurred within the first three days while the patient was in the hospital. (See  <a class="medical medical_review" href="/z/d/html/977.html" rel="external">"The management of atrial fibrillation in patients with heart failure"</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Postmyocardial infarction</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">Dofetilide</a> has been evaluated and appears safe for use in patients with a history of myocardial infarction (MI). The DIAMOND-MI trial enrolled 1510 patients with an acute MI and a left ventricular ejection fraction ≤35 percent. Patients were randomly assigned to dofetilide (500 mcg twice per day) or placebo within seven days of the MI [<a href="#rid41">41</a>]. The one year mortality was 31 percent, and the incidence of arrhythmic deaths was 17 percent. Total mortality, cardiac mortality, arrhythmic mortality, and the combined end point of cardiac death and resuscitation were the same in both groups. In addition, there was evidence of antiarrhythmic efficacy of dofetilide. Among patients receiving dofetilide, there was a lower incidence of new atrial fibrillation and a higher rate of conversion of atrial fibrillation to sinus rhythm (42.4 versus 12.5 percent for placebo).</p><p>Torsades de pointes developed in 0.9 percent of patients treated with <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>, most of which occurred within the first four days of treatment. However, the patients in this trial were scrutinized carefully to exclude those with known risk factors for torsade, which may explain why the incidence of torsade was lower than in some other studies noted above.</p><p class="headingAnchor" id="H2482418794"><span class="h2">Use of dofetilide in patients with left ventricular hypertrophy</span></p><p class="bulletIndent1"><span class="glyph">●</span>United States guidelines recommend avoiding pure class III antiarrhythmics such as <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> in patients with significant left ventricular hypertrophy (LVH) due to concerns for increased risk of death. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, in a propensity-matched cohort of 718 patients with AF and LVH, <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> was not associated with increased mortality at three years (the primary outcome). Patients (≥18 years of age with AF and LVH ≥1.4) were treated with dofetilide, and a control group of patients without a history of antiarrhythmic drug use were propensity matched. Total all-cause hospitalizations were higher in the control group, but hospitalizations for AF were no different. Given the current options available, these preliminary findings suggest that further studies of dofetilide in patients with LVH are reasonable for managing symptomatic AF [<a href="#rid42">42</a>]. </p><p></p><p class="headingAnchor" id="H9796647"><span class="h1">SAFETY</span><span class="headingEndMark"> — </span>There is concern about the safety of <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>, which like other class III antiarrhythmic agents  (<a class="graphic graphic_figure graphicRef64845" href="/z/d/graphic/64845.html" rel="external">figure 1</a>) is associated with a risk of torsades de pointes [<a href="#rid43">43,44</a>]. Torsades de pointes has been reported in up to 3 percent of patients receiving dofetilide [<a href="#rid15">15,45</a>]. In a pooled analysis from the dofetilide treated patients in the DIAMOND-HF and DIAMOND-MI trials (where the incidence of torsades de pointes was 2.1 percent), the risk of torsades de pointes was greater in women than in men (OR 2.2), and in patients with NYHA class III or IV heart failure (OR 3.2) [<a href="#rid46">46</a>]. Despite the increased risk of torsade de pointes, a pooled analysis of 1346 patients receiving dofetilide and 677 treated with placebo in randomized clinical trials did not show an increase in mortality with dofetilide use (adjusted hazard ratio 1.1) [<a href="#rid47">47</a>].</p><p>To evaluate the incidence and risk factors for in-hospital adverse events as well as the long-term safety of continued use of <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>, one study conducted a retrospective chart review of a cohort of 1404 patients initially receiving loading doses for AF suppression between 2008 and 2012 [<a href="#rid48">48</a>]. Of the 17 patients (1.2 percent) who developed torsades de pointes during loading, 10 had a cardiac arrest requiring resuscitation (with one death), five had syncope/presyncope, and two were asymptomatic. Dofetilide loading doses were stopped for 105 patients (7.5 percent) due to excessive QTc prolongation or torsades de pointes. Variables that correlated with torsades de pointes were female gender, 500 mcg dose, reduced ejection fraction, and increase in QTc from baseline. One-year all-cause mortality was higher in patients who continued dofetilide compared with those who discontinued use (HR 2.48, 95% CI 1.08 to 5.71, p = 0.03). Those patients who experienced a torsades de pointes event had higher one-year all-cause mortality than those who did not (17.6 versus 3 percent at one year, p&lt;0.001).</p><p>Because excessive QT prolongation is assumed to be a critical component of torsades de pointes, orally administered <a class="drug drug_general" data-topicid="9580" href="/z/d/drug information/9580.html" rel="external">magnesium citrate</a> has been used to shorten dofetilide-induced QT prolongation [<a href="#rid49">49</a>]. Intravenous magnesium may also increase the chemical cardioversion rate and lower the incidence of torsades de pointes [<a href="#rid50">50</a>]. (See <a class="local">'Oral dofetilide for atrial fibrillation/atrial flutter termination and prevention'</a> above.)</p><p class="headingAnchor" id="H1015043664"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112091.html" rel="external">"Society guideline links: Atrial fibrillation"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116931.html" rel="external">"Society guideline links: Supraventricular arrhythmias"</a>.)</p><p class="headingAnchor" id="H678448"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrophysiology </strong>– <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">Dofetilide</a> is a class III antiarrhythmic agent  (<a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">table 1</a>) that blocks the delayed rectifier cardiac potassium channel and increases the late sodium current, both actions that prolong repolarization. (See <a class="local">'Electrophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ventricular tachyarrhythmias </strong>– For patients who are candidates for other antiarrhythmic drugs (ie, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>, etc), we do not suggest the routine use of <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> as a first-line antiarrhythmic drug for the treatment of ventricular tachyarrhythmias. This is based on the lack of prospective efficacy data showing improvement in outcomes over other medications when dofetilide is used for the treatment of ventricular tachyarrhythmias. (See <a class="local">'Ventricular tachyarrhythmias'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protocol for administration </strong>– In an effort to optimize efficacy and safety, the initiation or reinitiation of <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> should occur in a controlled fashion according to the US Food and Drug Administration (FDA)-recommended dose protocol  (<a class="graphic graphic_figure graphicRef64845" href="/z/d/graphic/64845.html" rel="external">figure 1</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug approval and restrictions </strong>– The use of <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> is approved by FDA and several countries worldwide. Its use in the US is contingent upon the following restrictions (see <a class="local">'Drug approval and restrictions'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients must be hospitalized for a minimum of three days for <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> initiation to monitor creatinine clearance, QT interval, and cardiac rhythm  (<a class="graphic graphic_figure graphicRef64845" href="/z/d/graphic/64845.html" rel="external">figure 1</a>). Most episodes of torsades de pointes occur within this three day period, the time of peak increase in the QT interval, but rarely torsades de pointes can occur later. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hospitalization with monitoring is recommended when therapy has been interrupted and is to be reinitiated or when dose increase is considered necessary.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">Dofetilide</a> is <strong>contraindicated </strong>in patients with congenital long QT syndrome, a baseline QT interval or QTc &gt;440 msec (500 msec in patients with ventricular conduction abnormalities), severe renal insufficiency (CCr &lt;20 mL/min), known hypersensitivity, and in patients taking drugs known to slow its renal elimination (eg, <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">cimetidine</a>, <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>, <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a>, alone or in combination with sulfamethoxazole, <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">prochlorperazine</a>, <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">hydrochlorothiazide</a>, alone or in combination with <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">triamterene</a>, megestrol, <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a>, and <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific indications </strong>– <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">Dofetilide</a> appears to be safe for use in patients with a history of heart failure or prior myocardial infarction. In patients with heart failure, however, there is a suggestion of increased mortality in patients with a baseline corrected QT (QTc) interval &gt;479 milliseconds. (See <a class="local">'Heart failure'</a> above and <a class="local">'Postmyocardial infarction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Safety </strong>– Like other class III antiarrhythmic agents, <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> is associated with dose-dependent prolongation of the QT interval and a risk of torsades de pointes, which has been reported in up to 3 percent of patients receiving dofetilide. This risk may be attenuated with concomitant magnesium therapy, careful attention to modifiable risk factors, and participation of clinical pharmacists to help manage the treatment initiation protocol required by the FDA. (See <a class="local">'Safety'</a> above.) </p><p></p><p class="headingAnchor" id="H64151815"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Raymond Woosley, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mounsey JP, DiMarco JP. Cardiovascular drugs. Dofetilide. Circulation 2000; 102:2665.</a></li><li><a class="nounderline abstract_t">Carmeliet E. Use-dependent block of the delayed K+ current in rabbit ventricular myocytes. Cardiovasc Drugs Ther 1993; 7 Suppl 3:599.</a></li><li><a class="nounderline abstract_t">Kiehn J, Lacerda AE, Wible B, Brown AM. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. Circulation 1996; 94:2572.</a></li><li><a class="nounderline abstract_t">Yang T, Chun YW, Stroud DM, et al. Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current. Circulation 2014; 130:224.</a></li><li><a class="nounderline abstract_t">Démolis JL, Funck-Brentano C, Ropers J, et al. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation 1996; 94:1592.</a></li><li><a class="nounderline abstract_t">Abi-Gerges N, Small BG, Lawrence CL, et al. Evidence for gender differences in electrophysiological properties of canine Purkinje fibres. Br J Pharmacol 2004; 142:1255.</a></li><li><a class="nounderline abstract_t">Pokorney SD, Yen DC, Campbell KB, et al. Dofetilide dose reductions and discontinuations in women compared with men. Heart Rhythm 2018; 15:478.</a></li><li><a class="nounderline abstract_t">Sedgwick ML, Rasmussen HS, Cobbe SM. Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris. Am J Cardiol 1992; 69:513.</a></li><li><a class="nounderline abstract_t">Cobbe SM, Campbell RW, Camm AJ, et al. Effects of intravenous dofetilide on induction of atrioventricular re-entrant tachycardia. Heart 2001; 86:522.</a></li><li><a class="nounderline abstract_t">Smith DA, Rasmussen HS, Stopher DA, Walker DK. Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiotica 1992; 22:709.</a></li><li><a class="nounderline abstract_t">Rasmussen HS, Allen MJ, Blackburn KJ, et al. Dofetilide, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol 1992; 20 Suppl 2:S96.</a></li><li><a class="nounderline abstract_t">Le Coz F, Funck-Brentano C, Morell T, et al. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization. Clin Pharmacol Ther 1995; 57:533.</a></li><li><a class="nounderline abstract_t">Kobayashi Y, Atarashi H, Ino T, et al. Clinical and electrophysiologic effects of dofetilide in patients with supraventricular tachyarrhythmias. J Cardiovasc Pharmacol 1997; 30:367.</a></li><li><a class="nounderline abstract_t">Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol 1997; 29:385.</a></li><li><a class="nounderline abstract_t">Nørgaard BL, Wachtell K, Christensen PD, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am Heart J 1999; 137:1062.</a></li><li><a class="nounderline abstract_t">Frost L, Mortensen PE, Tingleff J, et al. Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group. Int J Cardiol 1997; 58:135.</a></li><li><a class="nounderline abstract_t">Bianconi L, Castro A, Dinelli M, et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur Heart J 2000; 21:1265.</a></li><li><a class="nounderline abstract_t">Walker DK, Alabaster CT, Congrave GS, et al. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug Metab Dispos 1996; 24:447.</a></li><li><a class="nounderline abstract_t">Varkevisser R, Houtman MJ, Linder T, et al. Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue. Br J Pharmacol 2013; 169:1322.</a></li><li><a class="nounderline abstract_t">Yu Z, Klaasse E, Heitman LH, Ijzerman AP. Allosteric modulators of the hERG K(+) channel: radioligand binding assays reveal allosteric characteristics of dofetilide analogs. Toxicol Appl Pharmacol 2014; 274:78.</a></li><li><a class="nounderline abstract_t">Hreiche R, Plante I, Drolet B, et al. Lengthening of cardiac repolarization in isolated guinea pigs hearts by sequential or concomitant administration of two IKr blockers. J Pharm Sci 2011; 100:2469.</a></li><li><a class="nounderline abstract_t">Mar PL, Horbal P, Chung MK, et al. Drug Interactions Affecting Antiarrhythmic Drug Use. Circ Arrhythm Electrophysiol 2022; 15:e007955.</a></li><li><a class="nounderline abstract_t">Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341:857.</a></li><li><a class="nounderline abstract_t">Turagam MK, Afzal MR, Reddy M, et al. Practice variation in the re-initiation of dofetilide: An observational study. Int J Cardiol 2017; 236:221.</a></li><li><a class="nounderline abstract_t">Cho JH, Youn SJ, Moore JC, et al. Safety of Oral Dofetilide Reloading for Treatment of Atrial Arrhythmias. Circ Arrhythm Electrophysiol 2017; 10.</a></li><li><a class="nounderline abstract_t">Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000; 102:2385.</a></li><li><a class="nounderline abstract_t">Khurshid S, Akerman S, Man JP, et al. Acute conversion of persistent atrial fibrillation during dofetilide loading does not predict long-term atrial fibrillation-free survival. J Interv Card Electrophysiol 2015; 42:117.</a></li><li><a class="nounderline abstract_t">Steinberg JS, Shah Y, Szepietowska B. Pharmacologic Conversion during Dofetilide Treatment for Persistent Atrial Fibrillation. Pacing Clin Electrophysiol 2017; 40:667.</a></li><li><a class="nounderline abstract_t">Qin D, Leef G, Alam MB, et al. Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation. J Cardiol 2016; 67:471.</a></li><li><a class="nounderline abstract_t">Shantha G, Chugh A, Crawford T, et al. Comparative Efficacy of Dofetilide Versus Amiodarone in Patients With Atrial Fibrillation. JACC Clin Electrophysiol 2021; 7:642.</a></li><li><a class="nounderline abstract_t">Sharma SP, Turagam M, Atkins D, et al. Safety of rapid switching from amiodarone to dofetilide in atrial fibrillation patients with an implantable cardioverter-defibrillator. Heart Rhythm 2019; 16:990.</a></li><li><a class="nounderline abstract_t">Tendera M, Wnuk-Wojnar AM, Kulakowski P, et al. Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo. Am Heart J 2001; 142:93.</a></li><li><a class="nounderline abstract_t">Andersen HR, Wiggers H, Knudsen LL, et al. Dofetilide reduces the incidence of ventricular fibrillation during acute myocardial ischaemia. A randomised study in pigs. Cardiovasc Res 1994; 28:1635.</a></li><li><a class="nounderline abstract_t">Boriani G, Lubinski A, Capucci A, et al. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Eur Heart J 2001; 22:2180.</a></li><li><a class="nounderline abstract_t">Mazur A, Anderson ME, Bonney S, Roden DM. Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation. J Am Coll Cardiol 2001; 37:1100.</a></li><li><a class="nounderline abstract_t">Baquero GA, Banchs JE, Depalma S, et al. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies. J Cardiovasc Electrophysiol 2012; 23:296.</a></li><li><a class="nounderline abstract_t">Wallace AA, Stupienski RF 3rd, Brookes LM, et al. Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs. J Cardiovasc Pharmacol 1991; 18:687.</a></li><li><a class="nounderline abstract_t">Rousseau MF, Massart PE, van Eyll C, et al. Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure. Am J Cardiol 2001; 87:1250.</a></li><li><a class="nounderline abstract_t">Koene RJ, Menon V, Cantillon DJ, et al. Clinical Outcomes and Characteristics With Dofetilide in Atrial Fibrillation Patients Considered for Implantable Cardioverter-Defibrillator. Circ Arrhythm Electrophysiol 2020; 13:e008168.</a></li><li><a class="nounderline abstract_t">Brendorp B, Elming H, Jun L, et al. Qtc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation 2001; 103:1422.</a></li><li><a class="nounderline abstract_t">Køber L, Bloch Thomsen PE, Møller M, et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 2000; 356:2052.</a></li><li><a class="nounderline abstract_t">Wann DG, Medoff BS, Mehdi NA, et al. Dofetilide use is not associated with increased mortality in patients with left ventricular hypertrophy and atrial fibrillation. J Cardiovasc Electrophysiol 2023; 34:447.</a></li><li><a class="nounderline abstract_t">Naksuk N, Sugrue AM, Padmanabhan D, et al. Potentially modifiable factors of dofetilide-associated risk of torsades de pointes among hospitalized patients with atrial fibrillation. J Interv Card Electrophysiol 2019; 54:189.</a></li><li><a class="nounderline abstract_t">Ko EYJ, Carpenter CM, Gagnon DJ, Andrle AM. Pharmacist-Managed Inpatient Dofetilide Initiation Program: Description and Adherence Rate Post-Root Cause Analysis. J Pharm Pract 2020; 33:784.</a></li><li><a class="nounderline abstract_t">Ferguson JJ. Meeting highlights. Highlights of the 71st scientific sessions of the American Heart Association. Circulation 1999; 99:2486.</a></li><li><a class="nounderline abstract_t">Pedersen HS, Elming H, Seibaek M, et al. Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. Am J Cardiol 2007; 100:876.</a></li><li><a class="nounderline abstract_t">Pritchett EL, Wilkinson WE. Effect of dofetilide on survival in patients with supraventricular arrhythmias. Am Heart J 1999; 138:994.</a></li><li><a class="nounderline abstract_t">Abraham JM, Saliba WI, Vekstein C, et al. Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter. Circ Arrhythm Electrophysiol 2015; 8:772.</a></li><li><a class="nounderline abstract_t">McBride BF, Min B, Kluger J, et al. An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence. Ann Noninvasive Electrocardiol 2006; 11:163.</a></li><li><a class="nounderline abstract_t">Coleman CI, Sood N, Chawla D, et al. Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation. Europace 2009; 11:892.</a></li></ol></div><div id="topicVersionRevision">Topic 1033 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11085972" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cardiovascular drugs. Dofetilide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8251429" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Use-dependent block of the delayed K+ current in rabbit ventricular myocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8921803" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24895457" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8840849" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15265803" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Evidence for gender differences in electrophysiological properties of canine Purkinje fibres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29605013" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Dofetilide dose reductions and discontinuations in women compared with men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1736617" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11602544" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effects of intravenous dofetilide on induction of atrioventricular re-entrant tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1441594" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1279316" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Dofetilide, a novel class III antiarrhythmic agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7768076" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9300322" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical and electrophysiologic effects of dofetilide in patients with supraventricular tachyarrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9014993" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10347332" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9049678" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10924317" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8801060" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23586323" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24200993" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Allosteric modulators of the hERG K(+) channel: radioligand binding assays reveal allosteric characteristics of dofetilide analogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21491454" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Lengthening of cardiac repolarization in isolated guinea pigs hearts by sequential or concomitant administration of two IKr blockers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35491871" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Drug Interactions Affecting Antiarrhythmic Drug Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10486417" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28233630" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Practice variation in the re-initiation of dofetilide: An observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29038104" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Safety of Oral Dofetilide Reloading for Treatment of Atrial Arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11067793" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25620152" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Acute conversion of persistent atrial fibrillation during dofetilide loading does not predict long-term atrial fibrillation-free survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28220940" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pharmacologic Conversion during Dofetilide Treatment for Persistent Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26233885" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33812835" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comparative Efficacy of Dofetilide Versus Amiodarone in Patients With Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30710741" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Safety of rapid switching from amiodarone to dofetilide in atrial fibrillation patients with an implantable cardioverter-defibrillator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11431663" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7842456" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Dofetilide reduces the incidence of ventricular fibrillation during acute myocardial ischaemia. A randomised study in pigs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11913480" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11263615" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21955243" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1723765" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11377349" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32538135" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical Outcomes and Characteristics With Dofetilide in Atrial Fibrillation Patients Considered for Implantable Cardioverter-Defibrillator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11245647" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Qtc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11145491" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36335642" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Dofetilide use is not associated with increased mortality in patients with left ventricular hypertrophy and atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30353374" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Potentially modifiable factors of dofetilide-associated risk of torsades de pointes among hospitalized patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30935279" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pharmacist-Managed Inpatient Dofetilide Initiation Program: Description and Adherence Rate Post-Root Cause Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10330376" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Meeting highlights. Highlights of the 71st scientific sessions of the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17719337" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10539835" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effect of dofetilide on survival in patients with supraventricular arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26063741" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16630091" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19351630" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
